Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — December 2022

Genmab — December 2022

Planlagt Fastgjort Låst Flyttet Genmab
668 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #122

    Im ok with the moon

    1 Reply Last reply
    0
    • nohopeN Offline
      nohopeN Offline
      nohope
      wrote on sidst redigeret af
      #123

      You are probably right, we have to go back 10 years to make it look great.I can´t do 10 years, but this 5 years compared to Novo, which steadily pays annual dividend.https://imgur.com/a/DSOpp2a

      1 Reply Last reply
      0
      • G Offline
        G Offline
        GeorgeBest
        wrote on sidst redigeret af
        #124

        5 years looks okay for. Can I get the same return the next 5 years, I’ll be happy 🙂

        1 Reply Last reply
        0
        • J Offline
          J Offline
          JKY_VH
          wrote on sidst redigeret af
          #125

          😄 Bulder

          1 Reply Last reply
          0
          • E Offline
            E Offline
            E_L
            wrote on sidst redigeret af
            #126

            Janssen Submits Biologics License Application to U.S. FDA for Talquetamab for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma https://www.prnewswire.com/news-releases/janssen-submits-biologics-license-application-to-us-fda-for-talquetamab-for-the-treatment-of-patients-with-relapsed-or-refractory-multiple-myeloma-301699241.html

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #127

              just a year after teclistamab; that was dec21 (and approved oct22)

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #128

                Thats really nice

                1 Reply Last reply
                0
                • nohopeN Offline
                  nohopeN Offline
                  nohope
                  wrote on sidst redigeret af
                  #129

                  Man skulle tro det var Novo der havde indsendt en BLA.

                  1 Reply Last reply
                  0
                  • V Offline
                    V Offline
                    Vitus
                    wrote on sidst redigeret af
                    #130

                    Ja, så er det godt man har APM og Vestas ….

                    1 Reply Last reply
                    0
                    • V Offline
                      V Offline
                      Vitus
                      wrote on sidst redigeret af
                      #131

                      Sådan tænker jeg ikke, når Genmab falder fra over kurs 3000 til under kurs 2000…

                      1 Reply Last reply
                      0
                      • G Offline
                        G Offline
                        gdn55
                        wrote on sidst redigeret af
                        #132

                        Men stiger fra 1875 til godt 3300 fra først i junni

                        1 Reply Last reply
                        0
                        • G Offline
                          G Offline
                          gdn55
                          wrote on sidst redigeret af
                          #133

                          Derfor er jeg langsigtet, har haft Genmab siden kurs 35,60.

                          1 Reply Last reply
                          0
                          • G Offline
                            G Offline
                            gentogen
                            wrote on sidst redigeret af
                            #134

                            The anti-interleukin (IL)-8 monoclonal antibody, BMS-986253 combined with nivolumab showed preliminary activity in melanoma progressing on checkpoint inhibitors, as reported in a phase I/II trial presented at ESMO Immuno-Oncology Congress 2022

                            1 Reply Last reply
                            0
                            • G Offline
                              G Offline
                              gentogen
                              wrote on sidst redigeret af
                              #135

                              Link Preview Image
                              Preliminary activity is reported with an anti-IL-8 monoclonal antibody plus nivolumab in melanoma

                              Combination therapy with BMS-986253 shows promise in patients progressing on checkpoint inhibitors

                              favicon

                              (dailyreporter.esmo.org)

                              1 Reply Last reply
                              0
                              • P Offline
                                P Offline
                                ProinvestorNEWS
                                wrote on sidst redigeret af
                                #136

                                Godmorgen 🙂 Opdateret status oversigt for det Danske OMX C25 Index fra NordStock fredag d. 9. december - købs- og salgsignaler: https://www.proinvestor.com/boards/107957/

                                1 Reply Last reply
                                0
                                • G Offline
                                  G Offline
                                  GeorgeBest
                                  wrote on sidst redigeret af
                                  #137

                                  Volume på Genmab ADS var vist ekstraordinær høj i går - næsten 1.4 mill. omsat

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    GeorgeBest
                                    wrote on sidst redigeret af
                                    #138

                                    Ret vildt at tænke på at når Epco og Talquetamab bliver godkendte i løbet af næste år, vil der være 8 Genmab udviklede produkter på markedet. Hvad mon bliver nr. 9. Mim8 fra Novo??

                                    1 Reply Last reply
                                    0
                                    • Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktørH Offline
                                      Helge_LarsenPI-redaktør
                                      wrote on sidst redigeret af
                                      #139

                                      Enig GB. Det er vildt og imponerende.

                                      1 Reply Last reply
                                      0
                                      • Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktørH Offline
                                        Helge_LarsenPI-redaktør
                                        wrote on sidst redigeret af
                                        #140

                                        Positive Early Results of Mim8 Pave Way for Testing in Phase 3 Trials https://hemophilianewstoday.com/news/mim8-well-tolerated-early-study-paving-way-phase-3-hemophilia-a-clinical-trials/

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #141

                                          on BMS-986253 https://clin.larvol.com/abstract-detail/ESMO-IO 2022/60866587 https://oncologypro.esmo.org/meeting-resources/esmo-immuno-oncology-congress/anti-il-8-bms-986253-nivolumab-nivo-ipilimumab-ipi-in-patients-pts-with-advanced-cancer-update-of-initial-phase-i-results

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper